SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

12 Feb 2025 Evaluate
The quarter ended December 2024 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 42080.00 millions.Net profit stood at Rs. 9846.70  millions  compared to Rs. 9164.40 millions in the corresponding previous quarter,high by 7.45%.Operating profit surged to 14663.50 millions from the corresponding previous quarter of 12405.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 42080.00 41157.50 2.24 124818.30 112706.20 10.75 146665.00 112588.30 30.27
Other Income 553.00 231.60 138.77 1270.00 765.00 66.01 1067.30 912.60 16.95
PBIDT 14663.50 12405.00 18.21 38516.10 28341.00 35.90 35657.90 11739.20 203.75
Interest 195.50 113.60 72.10 506.50 428.60 18.18 563.50 984.40 -42.76
PBDT 13695.80 12291.40 11.43 37237.40 27912.40 33.41 35094.40 10754.80 226.31
Depreciation 1525.20 1451.80 5.06 4397.10 4347.10 1.15 7247.50 5483.40 32.17
PBT 12170.60 10839.60 12.28 32840.30 23565.30 39.36 27846.90 5271.40 428.26
TAX 2323.90 1675.20 38.72 6024.20 4145.20 45.33 4586.00 1019.30 349.92
Deferred Tax 66.60 -170.90 -138.97 155.50 -4.70 -3408.51 -254.50 60.40 -521.36
PAT 9846.70 9164.40 7.45 26816.10 19420.10 38.08 23260.90 4252.10 447.04
Equity 912.50 910.70 0.20 912.50 910.70 0.20 911.40 910.00 0.15
PBIDTM(%) 34.85 30.14 15.61 30.86 25.15 22.71 24.31 10.43 133.18

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×